FDA New Drug and Biologic Approvals, 2018 Midyear Review

Mary L Windle, PharmD

Disclosures

August 01, 2018

In This Article

Onchocerciasis: Moxidectin

Indication: Indicated for treatment of onchocerciasis (river blindness) due to Onchocerca volvulus in patients aged 12 years or older.

Mechanism: Moxidectin, a macrocyclic lactone, is an anthelmintic drug. It is closely related to ivermectin, but provides a more sustained reduction in microfilarial levels. The precise mechanism in unknown.

Dosage: 8 mg (four 2-mg tablets) PO as a single dose administered with or without food.

Approval was based on a double-blind, parallel group, superiority trial (N=1472) that compared moxidectin (8 mg PO once) with ivermectin (150 mcg/kg PO once). The trial took place in Ghana, Liberia, and the Democratic Republic of the Congo. Results showed skin microfilarial loads (ie, parasite transmission reservoir) were lower from month 1 to month 18 after moxidectin treatment than after ivermectin treatment, with an 86% difference at month 12. Moxidectin would therefore be expected to reduce parasite transmission between treatment rounds more than ivermectin could, thus accelerating progress towards elimination.

Reference:

  • Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018 Jan 17. pii: S0140-6736(17)32844-1. https://www.ncbi.nlm.nih.gov/pubmed/29361335

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....